|
|
Executive Summary: Inaugural DSEC Member Retreat
On June 10-11, 2008 the Drug Safety Executive Council (DSEC) brought together leading safety experts from across the biopharmaceutical industry at the inaugural DSEC Member Retreat, “Confronting Major Safety Issues of the 21st Century.” The meeting was held at the Hyatt Regency at Penn’s Landing in Philadelphia, PA.
Summit participants included senior safety executives from a broad range of large biopharmaceutical companies, including Amgen, Astellas, AstraZeneca, Bayer Healthcare, Biogen Idec, Boehringer-Ingelheim, Genzyme, GlaxoSmithKline, Pfizer, Procter & Gamble, Roche, Shire, Takeda, UCB, and Wyeth. Also participating were numerous senior executives from other industry organizations with a vested interest in drug safety, including Baxter Healthcare, Cellumen, iCardiac, the National Institutes of Health (NIH), and the Critical Path Institute. The Summit agenda was crafted in close cooperation with the DSEC Advisory Board, led by Chairman Dr. Jack Reynolds, and including representatives from several of the large biopharmaceutical companies listed above, as well as Eli Lilly, F. Hoffman-La Roche, Johnson & Johnson, Sanofi-Aventis, and Schering-Plough.
If you would like to download a complete copy of this executive summary, please fill out the information below:
|